BMC Infectious Diseases · 2013 · 35 citations · 11 references
Life SciencesInfectious DiseasesMicrobiologyAntimicrobial ResistanceMolecular VirologyVirologyAntiviral Drug ResistanceAntiviral PharmacologyAntiviral PharmacotherapyAntiviral ResistanceAntiviral TherapyViral InfectionsAntiviral Resistance MutationsAntiviral TherapeuticsCytomegalovirus TherapyPost-transplant Cytomegalovirus InfectionResistance To Viral InfectionResistance-associated MutationsResistance-associated Viral VariantsTreatment Of Cytomegalovirus Infection
BACKGROUND: Human cytomegalovirus infections are still significant causes of morbidity and mortality in transplant recipients. The use of antiviral agents is limited by toxicity and evolving resistance in immunocompromised patients with ongoing viral replication during therapy. Here, we present the first documented case of genotypic resistance against maribavir in a bone marrow transplant (BMT) recipient. CASE PRESENTATION: The female 13-year-old patient was suffering from a refractory cytopenia. Ganciclovir, foscarnet, cidofovir, leflunomide and maribavir, an inhibitor of the cytomegalovirus UL97 protein, were administered to treat a therapy-resistant cytomegalovirus infection. Viral mutations conferring resistance against nucleotide and pyrophosphate analogs as well as maribavir (MBV) have evolved sequentially. Particularly, impressive was the fast emergence of multiple mutations T409M, H411Y and H411N conferring maribavir resistance after less than 6 weeks. CONCLUSION: We describe the fast emergence of cytomegalovirus variants with different maribavir resistance associated mutations in a bone marrow transplant recipient treated with MBV 400 mg p.o. twice per day. The results suggest that a high virus load permitted a selection of several but distinct therapy-resistant HCMV mutants. Since a phase II study with MBV is intended for the treatment of resistant or refractory HCMV infections in transplant recipients this has to be kept in mind in patients with high viral loads during therapy (NCT01611974).
11
Karen K. Biron, Stanley C. Chamberlain, Steven S. Good et al. · Antimicrobial Agents and Chemotherapy · 2002 · 364 citations · Full text
Francisco M. Marty, Per Ljungman, Genovefa A. Papanicolaou et al. · The Lancet Infectious Diseases · 2011 · 350 citations
Drew J. Winston, Jo‐Anne H. Young, Vinod Pullarkat et al. · Blood · 2008 · 245 citations · Full text
Jacob Lalezari, Judith A. Aberg, Laurene H. Wang et al. · Antimicrobial Agents and Chemotherapy · 2002 · 151 citations · Full text
Laurene H. Wang, Richard Peck, Yin Yin et al. · Antimicrobial Agents and Chemotherapy · 2003 · 134 citations · Full text